Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
5 NC counties and 1 VA county are under alert, including Cumberland, Johnston, Harnett, and Sampson counties.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ligand Pharm
(NQ:
LGND
)
86.06
+1.04 (+1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ligand Pharm
< Previous
1
2
3
Next >
Ligand to Report Fourth Quarter Financial Results on February 17
February 09, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
December 22, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand and GSK Expand Global Collaboration and License Agreement
December 21, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Third Quarter 2021 Financial Results
November 09, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
November 09, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Third Quarter Financial Results on November 9, 2021
October 26, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
October 21, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
August 30, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
August 16, 2021
From
Ligand Pharmaceuticals
Via
Business Wire
Ligand Reports Second Quarter 2021 Financial Results
July 29, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
July 21, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
July 19, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Second Quarter Financial Results on July 29, 2021
July 16, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
July 14, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports First Quarter 2021 Financial Results
May 03, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report First Quarter Financial Results on May 3, 2021
April 22, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.